32
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Detect adverse drug reactions for drug Atorvastatin

      Preprint
      ,

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Adverse drug reactions (ADRs) are big concern for public health. ADRs are one of most common causes to withdraw some drugs from markets. Now two major methods for detecting ADRs are spontaneous reporting system (SRS), and prescription event monitoring (PEM). The World Health Organization (WHO) defines a signal in pharmacovigilance as "any reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously". For spontaneous reporting systems, many machine learning methods are used to detect ADRs, such as Bayesian confidence propagation neural network (BCPNN), decision support methods, genetic algorithms, knowledge based approaches, etc. One limitation is the reporting mechanism to submit ADR reports, which has serious underreporting and is not able to accurately quantify the corresponding risk. Another limitation is hard to detect ADRs with small number of occurrences of each drug-event association in the database. In this paper we propose feature selection approach to detect ADRs from The Health Improvement Network (THIN) database. First a feature matrix, which represents the medical events for the patients before and after taking drugs, is created by linking patients' prescriptions and corresponding medical events together. Then significant features are selected based on feature selection methods, comparing the feature matrix before patients take drugs with one after patients take drugs. Finally the significant ADRs can be detected from thousands of medical events based on corresponding features. Experiments are carried out on the drug Atorvastatin. Good performance is achieved.

          Related collections

          Most cited references7

          • Record: found
          • Abstract: found
          • Article: not found

          Adverse drug reactions: role of pharmacogenomics.

          Adverse drug reactions (ADRs) are a significant cause of morbidity and mortality. The majority of ADRs can be considered common disorders with considerable clinical variability (clinical phenotype) in which many different genes are involved together with environmental variables. Pharmacogenomics is the study of how genes affect the individual response to drugs. There is some evidence that in the future the use of pharmacogenomics could help to reduce ADRs, as it aims to predict which patients are likely to respond to a particular drug and which patients are likely to have significant ADRs. In this article some examples of genetic polymorphisms affecting drug kinetics, drug toxicity and hypersensitivity related to ADRs are illustrated.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.

            The detrimental effects of adverse drug reactions (ADRs) are well established. Hence, precise and accurate assessment of ADRs' causality which can differentiate signal from noise is crucial in screening, management and minimisation of ADRs.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.

              Rosuvastatin is a lipid-lowering drug, the newest of a class of drugs called HMG-CoA reductase inhibitors, or 'statins', launched in the UK in March 2003. Our objective was to monitor the post-marketing safety of this drug, prescribed in primary care in England, using prescription-event monitoring.
                Bookmark

                Author and article information

                Journal
                30 August 2013
                Article
                1308.6697
                330e5384-7737-4b1f-920a-4fc41f3a9e1b

                http://arxiv.org/licenses/nonexclusive-distrib/1.0/

                History
                Custom metadata
                Fifth International Symposium on Computational Intelligence and Design (ISCID), 213-216, 2012. arXiv admin note: substantial text overlap with arXiv:1308.5144
                cs.CE

                Comments

                Comment on this article